NCT00520910

Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Conditions

• Aging
• Skin Abnormalities

Interventions

Type	Name	Description
DRUG	Polypodium leucotomos	Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.

Timeline

• Start date: 2007-08-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2007-08-27
• Last updated: 2019-06-18
• Results posted: 2019-06-18

Locations

1 site across 1 country: United States